Something else? Ask Aunt Vadge – bottom left of your screen!
Aloe vera turns up constantly in ‘natural antibiotic’ lists, and the latest interest is in whether it can break down biofilms, the slimy, glued-together bacterial cities that can make infections so hard to shift.
The short answer from the lab is a qualified yes: aloe vera and its active compounds, particularly the anthraquinone aloe-emodin, do show real antibiofilm activity in test-tube studies.2,3,4 But the effect is mostly about stopping biofilms from forming in the first place rather than busting established ones. In at least one head-to-head plant-extract study, aloe was the weakest performer of the bunch.1
Long-used and much-loved aloe is a promising laboratory candidate, and for biofilms, we see some useful applications. Here is what the evidence says.
Does aloe vera break down biofilms?
This is where it pays to read the studies carefully rather than the headlines.
The leaf-extract study that kicked it off
A 2011 laboratory study tested six medicinal leaf extracts, including aloe vera, betel, banana, tea, curry and peppermint, against biofilms formed by Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli and Bacillus subtilis, alone and in combination.1
Aloe vera came last. It inhibited the biofilm of just one of the bacterial combinations tested, while curry leaf was the standout and tea, betel and banana all outperformed it.1
That study is worth flagging for what it is: a small, single-author paper in a low-impact journal, with results judged by eye rather than measured, and no statistical analysis. It is a starting point for ideas, not strong evidence. Taken on its own, it would suggest aloe is a poor biofilm-buster.
What the wider research shows
Look beyond that one paper and the picture improves, with an important catch. A 2022 study on aloe vera extract against drug-resistant Gram-negative bacteria from urinary tract infections found strong inhibition of biofilm formation, blocking 93 to 100 per cent of biofilm build-up at higher concentrations.3
But when the same researchers tried the extract on biofilms that had already formed, they saw no effect at all.3 Their conclusion was blunt: aloe might help prevent bacteria from settling and building a biofilm, but it should not be relied on to destroy one that already exists.3
Other work is more encouraging on established biofilms. Aloe vera inner gel has shown antibiofilm activity against clinical strains of S. aureus, P. aeruginosa and the yeast Candida albicans grown in their sticky, surface-attached (sessile) form, with a general drop in bacterial biomass.2
Prevention, not demolition
Pulling those studies together, a consistent theme emerges. Aloe is reasonably good at stopping biofilms forming and at knocking back free-floating bacteria, and patchier at tearing down a mature, fully built biofilm.2,3
For a condition like bacterial vaginosis (BV), where the established biofilm is a larger problem, that is a meaningful limitation, not a footnote.
How aloe’s compounds work
Aloe vera is not one substance, but a mix of active compounds, and the antibiofilm credit largely goes to its anthraquinones (chiefly aloe-emodin and aloin).2 These two have a structure similar to tetracycline antibiotics and appear to work in a comparable way, interfering with bacterial protein production.2
Aloe-emodin in particular has been studied closely. Against Staphylococcus epidermidis, it damaged the bacterial cell membrane, deformed the cells and switched off genes involved in biofilm formation.4 In the urinary-tract study, aloe-emodin and its derivatives made up around three-quarters of the extract, which helps explain where the activity comes from.3
The other compound often named with aloe is acemannan, the large sugar molecule in the gel credited with its soothing and immune-modulating effects.
In the antibiofilm studies, though, the activity was pinned mainly on the anthraquinones rather than on acemannan,2 which is a reminder that ‘aloe vera’ covers a whole pharmacy of molecules, and a bottle of supermarket gel is not the same thing as a standardised, anthraquinone-rich extract used in a lab.
Can aloe vera help with BV, AV or yeast biofilms?
We do not yet have the studies to say. The biofilm research on aloe has mostly used skin, gut and urinary-tract bacteria, not the specific organisms that drive vaginal dysbiosis, so any link to BV or AV is an extrapolation at this stage.1,2,3,4
Where it gets interesting for yeast
The yeast angle has slightly more behind it. To build a biofilm, Candida albicans has to switch from its round form into long filaments by forming germ tubes, and that switch is essential to its ability to cause infection.5
An aloe vera leaf extract has been shown to suppress both Candida growth and germ-tube formation in the lab, hinting at a way to interrupt yeast biofilm at the very first step.5 For recurrent yeast infections, that mechanism is pointing in a useful direction.
The bigger picture for BV
The reason any of this is being pursued is that antibiotics are not solving recurrent BV. A 2024 systematic review of antibiofilm agents for BV grouped the candidates into antibiotics, antiseptics, peptides, enzymes, plant extracts, probiotics and surfactants, and noted that earlier hopes for antibiotics having useful antibiofilm activity have not held up. Plant extracts sit squarely in the list of options still being explored.6
The catch for any plant-based approach is matching the chemistry to the target. The vaginal biofilm in BV is a different beast to a skin or gut biofilm, with its own dominant species and its own matrix, so an extract that prevents E. coli attaching to a urinary catheter will not automatically dismantle a Gardnerella biofilm welded to the vaginal wall.3,6 That gap between general antibiofilm chemistry and vaginal-specific evidence is the whole reason we hedge here.
What this means
Aloe vera has real antibiofilm chemistry, and we are glad researchers are taking plant compounds seriously as antibiotics keep losing ground. In our experience here at My Vagina, many resilient vaginal infections are made more difficult to treat due to persistent biofilms, so any tool that interferes with biofilm, naturally derived or not, is worth watching.
That said, the current evidence is early, in vitro, and mostly about the wrong bacteria for a vaginal context. Aloe looks better at prevention than eradication, and there is no good evidence that using aloe gel inside the vagina prevents or treats BV, AV or yeast.
Aloe latex taken orally is also a strong laxative and is not a casual supplement. This is not a treatment you can buy off this idea, and biofilm-based infections need a proper plan, not a single ingredient.
Frequently asked questions
Can I put aloe vera gel in my vagina to treat BV?
We have no reason to recommend aloe vera vaginally for AV, BV or yeast infections at this time. The antibiofilm research on aloe is laboratory work using non-vaginal bacteria, and none of it tested aloe inside a human vagina.1,2,3 Recurrent BV is biofilm-driven and needs a structured approach, ideally guided by a practitioner and good testing.
Does aloe vera kill bacteria, or just stop biofilms forming?
Both, to a degree, but it is stronger at the second job. Aloe extracts can inhibit and kill free-floating bacteria, and they are good at blocking new biofilm from forming, but at least one study found no effect on biofilm that had already established.3
Which part of aloe vera has the antibiofilm activity?
Mostly the anthraquinones, aloe-emodin and aloin, which behave a bit like tetracycline antibiotics and disrupt bacterial protein production and cell membranes.2,4
Is aloe better for yeast or for bacterial infections?
The yeast evidence is arguably the more promising, because aloe can block the germ-tube switch Candida uses to build biofilm.5 But this is still lab work, not an avenue for treatment.
Why do antibiotics fail against vaginal biofilms?
The biofilm matrix physically shields the bacteria inside, so antibiotics cannot reach them at effective levels, which is a key reason BV comes back so often.6
What to do next
If you are stuck in a cycle of BV, AV or recurrent yeast that keeps returning after treatment, a biofilm is often part of the story, and so is whatever is driving the dysbiosis underneath it. The most useful first step is usually a thorough look at what is growing.
See how to get a thorough PCR or NGS vaginal microbiome test, enrol in Killing BV – our free program to learn what to do with recurrent BV and AV, and if you’re lost, book an appointment with our expert practitioners. They help people like you every day.
For tailored help, you can use Aunt Vadge’s Assistant, the chat widget in the bottom left of your screen. Aloe research is moving, antibiotics are not keeping up with recurrent dysbiosis, and we are keen to see where the plant-compound work ends up.
This is general information, not a substitute for personalised medical advice. If you have symptoms or concerns, please see your healthcare provider.
- Agrawal I. Susceptibility of bacterial biofilms against some leaf extracts. Plant Sciences Feed. 2011;1(5):69–73.
- Cataldi V, Di Bartolomeo S, Di Campli E, Nostro A, Cellini L, Di Giulio M. In vitro activity of Aloe vera inner gel against microorganisms grown in planktonic and sessile phases. Int J Immunopathol Pharmacol. 2015;28(4):595–602.
- Arsene MMJ, Podoprigora IV, Senyagin AN, et al. Phytochemical Analysis, Antibacterial and Antibiofilm Activities of Aloe vera Aqueous Extract against Selected Resistant Gram-Negative Bacteria Involved in Urinary Tract Infections. Fermentation. 2022;8(11):626.
- Li T, Lu Y, Zhang H, et al. Antibacterial Activity and Membrane-Targeting Mechanism of Aloe-Emodin Against Staphylococcus epidermidis. Front Microbiol. 2021;12:621866.
- Bernardes I, Felipe Rodrigues MP, Bacelli GK, Munin E, Alves LP, Costa MS. Aloe vera extract reduces both growth and germ tube formation by Candida albicans. Mycoses. 2012;55(3):257–261.
- Gao M, Manos J, Whiteley G, Zablotska-Manos I. Antibiofilm Agents for the Treatment and Prevention of Bacterial Vaginosis: A Systematic Narrative Review. J Infect Dis. 2024;230(3):e508–e517.
